Amrize Ltd (AMRZ) Stock Analysis
Is AMRZ a good investment?
Amrize Ltd (AMRZ) has a Plutrex AI rating of 74.0/100 as of August 20, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: PEG ratio of 0.90 is 61.5% below the industry average of 2.34 — AMRZ is the most attractively priced growth stock in the Construction Materials sector on a growth-adjusted basis, with 16.82% five-year EPS growth (50.5% above peers) priced at only 20.78x earnings vs. the industry's 29.33x; analyst consensus target of $57.65 implies 27.4% upside from $45.26. Main concern: Q2 EPS of $0.88 missed consensus of $0.92 by 4.3% (headline: 'Amrize Ltd (AMRZ) Misses Q2 Earnings Estimates'), and the stock has now declined ~14.4% from our first report ($52.88 → $45.26) while the analyst target has compressed 7.0% ($61.98 → $57.65) — the persistent earnings miss pattern combined with Building Envelope segment headwinds from roofing weakness (headline: 'Amrize Q2 Earnings Call Highlights') creates near-term fundamental uncertainty that limits conviction.
Investment Summary
AMRZ remains a fundamentally undervalued Construction Materials company trading at $45.26 with a PEG ratio of 0.90 — 61.5% below the industry average of 2.34 — while projecting 16.82% five-year EPS growth that is 50.5% above the peer average of 11.18%. The analyst consensus target of $57.65 implies 27.4% upside. The stock has declined a further 2.4% since our prior report ($46.37 → $45.26), with the analyst target compressing modestly from $58.76 to $57.65 (-1.9%). Core fundamentals are essentially unchanged: FCF of $1.134B, D/E of 0.39 (vs. industry 1.21), $729M cash, and P/E of 20.78x vs. the industry's 29.33x. The Q2 EPS miss ($0.88 vs. $0.92 consensus, -4.3%) and Building Envelope segment headwinds from roofing weakness remain the primary near-term concerns, but the Texas cement plant expansion and vertical integration acquisition signal management's confidence in long-term growth. The investment thesis is intact: a high-growth, conservatively financed sector outlier trading at a steep discount to peers on every growth-adjusted valuation metric.
Key Strengths
- PEG ratio of 0.90 is 61.5% below the industry average of 2.34 — AMRZ is the most attractively priced growth stock in the Construction Materials sector on a growth-adjusted basis, with 16.82% five-year EPS growth (50.5% above peers) priced at only 20.78x earnings vs. the industry's 29.33x; analyst consensus target of $57.65 implies 27.4% upside from $45.26
- Fortress balance sheet: FCF of $1.134B, $729M cash, and D/E of 0.39 (67.7% below the industry average of 1.21) — the Texas cement plant expansion and vertical integration acquisition demonstrate management's ability to deploy capital strategically while maintaining conservative leverage that over-leveraged peers cannot match in a cyclical downturn
- Historical earnings growth of 14.7% is 517% above the industry average of 2.38%, and the share cancellation program signals management confidence in cash generation — operating margin of 20.49% (8.5% above the industry average of 18.88%) demonstrates proven cost discipline that supports the credibility of 16.82% five-year EPS growth projections
Key Concerns
- Q2 EPS of $0.88 missed consensus of $0.92 by 4.3% (headline: 'Amrize Ltd (AMRZ) Misses Q2 Earnings Estimates'), and the stock has now declined ~14.4% from our first report ($52.88 → $45.26) while the analyst target has compressed 7.0% ($61.98 → $57.65) — the persistent earnings miss pattern combined with Building Envelope segment headwinds from roofing weakness (headline: 'Amrize Q2 Earnings Call Highlights') creates near-term fundamental uncertainty that limits conviction
- ROE of 9.53% remains 60.9% below the industry average of 24.40%, gross margin of 25.02% is 26% below the industry average of 33.81%, and the 10.6pp gap between operating margin (20.49%) and net margin (9.89%) indicates structural non-operating charges — these profitability deficits constrain the path to multiple expansion and make the stock dependent on sustained EPS growth delivery to justify re-rating
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
AMRZ's fundamentals present a consistent picture with our prior report. Valuation: P/E of 20.78x (vs. industry 29.33x, a 29.1% discount) paired with PEG of 0.90 (vs. industry 2.34, a 61.5% discount) — the market is pricing AMRZ as if it were a slow-growth utility despite 16.82% five-year forward EPS growth. Profitability: Gross margin of 25.02% remains 26% below the industry average of 33.81%, a structural weakness. Operating margin of 20.49% is 8.5% above the industry average of 18.88%, demonstrating exceptional SG&A discipline. Net margin of 9.89% is 13.9% below the industry average of 11.48%, with the 10.6pp gap between operating and net margins indicating meaningful interest/tax drag. ROE of 9.53% is 60.9% below the industry average of 24.40% — the most persistent structural concern, though partially explained by the company's conservative D/E of 0.39 vs. peers at 1.21 (lower leverage mechanically suppresses ROE). Growth: Historical earnings growth of 14.7% (vs. industry 2.38%), forward next-year EPS growth of 15.78% (vs. industry 16.50%), and five-year EPS growth of 16.82% (vs. industry 11.18%). Revenue growth of 8.6% trails the industry's 10.04%. Financial Health: FCF of $1.134B, cash of $729M, D/E of 0.39 — the strongest balance sheet in the peer group. Implied EPS of ~$2.18 growing at 16.8% for five years reaches ~$4.74; at a conservative 20x exit multiple, intrinsic value approximates $94.80 on a five-year horizon, or ~$58-62 discounted at 10% annually — consistent with the $57.65 analyst target.
News Sentiment
Amrize Ltd. is navigating a tricky stretch — delivering solid long-term growth while stumbling on short-term earnings expectations. The company's second-quarter results, detailed in 'Amrize Reports Second Quarter 2026 Results,' showed the business is fundamentally healthy, but the headline from 'Amrize Ltd (AMRZ) Misses Q2 Earnings Estimates' tells the uncomfortable truth: earnings of $0.88 per share fell short of Wall Street's $0.92 target by about 4 cents, or 4.3%. That's not catastrophic, but it's the kind of miss that makes investors nervous — especially when it's a recurring theme. The culprit? The 'Amrize Q2 Earnings Call Highlights' pointed to weakness in the Building Envelope segment, where roofing demand has softened, creating a drag on otherwise solid performance. But here's the flip side: Amrize isn't standing still. The company is aggressively expanding in Texas, combining a new cement plant expansion in Midlothian with a fresh acquisition that adds ready-mix concrete production — a smart vertical integration play that locks in customers from raw materials all the way to finished product. Meanwhile, management is buying back shares, a move that signals confidence in the company's cash-generating engine. The 'Oakmark Global Strategy Q2 2026 Portfolio Activity' report noted institutional interest in the stock. Bottom line for everyday investors: Amrize is a company with real long-term potential that's hitting some near-term speed bumps. The stock is down roughly 14% from its recent highs, which may be creating an opportunity — but patience is required while the roofing headwinds work themselves out.
Risk Assessment
Primary risks: (1) Continued EPS misses — if Q3 also disappoints, the 16.82% five-year EPS growth projection loses credibility and the PEG-based undervaluation thesis weakens; stop-loss at $40.50 (~10.2% below entry) addresses this scenario, representing approximately 1.86x book value — a reasonable floor given $1.134B FCF. (2) Building Envelope segment roofing weakness could persist through H2 2026, pressuring near-term margins and potentially triggering further analyst target compression. (3) Gross margin of 25.02% (26% below peers) leaves limited buffer against input cost inflation in a cyclical materials sector. (4) ROE of 9.53% vs. industry 24.40% — if the company cannot improve equity returns, the stock may remain structurally discounted. Mitigants: D/E of 0.39 provides balance sheet resilience; Texas cement plant expansion and vertical integration acquisition strengthen long-term competitive positioning; $729M cash provides optionality; PEG of 0.90 already prices in significant skepticism. Position size reduced to 3.0% (from prior 3.5%) to reflect the persistent earnings miss pattern.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is AMRZ a halal stock?
No, Amrize Ltd (AMRZ) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for AMRZ?
Amrize Ltd (AMRZ) has a Plutrex AI rating of 74.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is AMRZ a good investment?
According to Plutrex AI, AMRZ has a Buy rating (74.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in AMRZ?
US stocks like AMRZ can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in AMRZ?
Plutrex AI identifies the main risks for AMRZ by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.